HVH-2930

Overview

HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis , and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab ( HY-P9907 ). HVH-2930 is applicable to relevant research on breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Survivin | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > HSP | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-161781
• CAS No.: 3034605-72-3
• Molecular Formula: C29H36N4O3
• Molecular Weight: 488.62
• Purity: 96.54%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
• Availability: In-stock

Source

Original product source